

Source: Refinitiv

Market data

EPIC/TKR	OXB
Price (p)	732
12m High (p)	1,064
12m Low (p)	581
Shares (m)	76.7
Mkt Cap (£m)	561.7
EV (£m)	516.2
Free Float	59.3%
Market	LSE

Description

OXB is a UK-based biopharmaceutical company specialising in cell and gene therapies developed using the LentiVector platform, technology for creation of gene-delivery vehicles based on viruses. In addition to vector development and manufacture, OXB has a pipeline of therapeutic candidates and undertakes innovative pre-clinical R&D in gene-medicine.

Company information

CEO	John Dawson
CFO	Stuart Paynter
Chairman	Lorenzo Tallarigo
	+44 1865 783 000
	www.oxfordbiomedica.co.uk

Key shareholders

Directors	0.3%
Vulpes	15.2%
M&G	15.1%
Novo Holdings A/S	10.1%
Canaccord Genuity	4.3%
Aviva	3.4%
Hargreaves Lansdown	3.2%

Diary

Est. Sep'19	Interim Results
-------------	-----------------

Analysts

Martin Hall	020 7194 7632	mh@hardmanandco.com
Dorothea Hill	020 7194 7626	dnh@hardmanandco.com
Grégoire Pavé	020 7194 7628	gp@hardmanandco.com

OXFORD BIOMEDICA

De-leveraging the balance sheet

Oxford BioMedica (OXB) is a specialist, advanced therapy, viral-vector biopharma company. It offers vector manufacturing and development services, while developing proprietary drug candidates, with its LentiVector® platform. 2018 saw significant growth in gross income, primarily through licensing deals, to deliver OXB's first underlying operating profit. OXB is, however, carrying a significant loan of \$55m, which is relatively expensive with an interest rate of 9% plus US LIBOR, and also exposes it to forex risk. Equity financing of £53.5m from Novo Holdings A/S has been agreed, allowing repayment of the loan and securing a strategic partner.


- **Strategy:** OXB has four strategic objectives: i) delivery of vector development services that embed its technology within partners' commercial products; ii) bioprocessing and commercial manufacture of vector; iii) out-licensing of proprietary candidates; and iv) investment in R&D and the LentiVector platform.
- **Equity investment:** OXB has signed an agreement with Novo Holdings A/S for an equity investment of £53.5m, at £6.90/share, representing 10.1% of OXB's enlarged share capital. This greatly strengthens the balance sheet and is a clear demonstration of the industry's confidence in OXB's growth potential.
- **Balance sheet:** With the new cash arriving at the start of June, the loan is likely to be paid off as soon as possible, leaving the interim balance sheet ungeared and with gross cash driven by Capex timing and the cost of the fundraise. With the removal of ongoing interest payments, free cashflow forecasts are positive from 2020.
- **Risks:** OXB's mid-term sales model is dependent on successful progress of partners' clinical trials and commercialisation of LentiVector-enabled products. OXB is investing heavily in infrastructure for manufacturing capacity and in personnel, which will affect the bottom line.
- **Investment summary:** OXB is an exciting company with market-leading technology. It has been extensively validated through large deals with leading (bio)pharmaceutical partners and through grants from the UK government. On expectations of further milestones in 2019, OXB is now profitable, net cash positive and cashflow positive at the operating level.

Financial summary and valuation

Year-end Dec (£m)	2016	2017	2018	2019E	2020E	2021E
Gross income (as reported)	30.78	39.36	67.84	83.47	104.60	123.04
Group sales	27.78	31.49	39.63	54.13	78.70	89.80
EBITDA	-6.78	-2.63	13.54	14.63	18.53	30.40
Underlying EBIT	-10.45	-7.00	9.18	9.84	13.27	25.16
Statutory EBIT	-11.32	-7.97	7.93	8.50	11.82	23.62
Underlying PBT	-15.34	-16.38	4.57	7.67	13.66	25.71
Statutory PBT	-20.31	-11.76	5.01	5.93	12.21	24.16
Underlying EPS (p)	-21.00	-21.99	10.88	13.68	24.35	43.08
Statutory EPS (p)	-29.95	-14.56	11.57	11.27	22.17	40.75
Net (debt)/cash	-19.05	-22.54	-8.91	34.80	43.82	64.93
Capital increase	17.50	0.39	19.81	52.43	0.10	0.10
P/E (x)	-	-	67.27	53.53	30.06	16.99
EV/sales (x)	-	-	-	9.54	6.56	5.75


Source: Hardman & Co Life Sciences Research

Sales and gross margin



- ▶ Oxford BioMedica’s sales are from bioprocessing (and commercial development) fees, plus additional income such as licensing upfronts and development milestones
- ▶ Royalties are receivable once partners’ therapies reach the market, with royalties from Novartis being received already
- ▶ The gross margin has dipped through investment in infrastructure and bioprocessing technology, but is likely to trend higher towards 50%-60% when operating at full capacity

R&D investment



- ▶ Underlying R&D spend, mostly on bioprocessing, was £30m in FY’18
- ▶ In addition to the LentiVector platform, OXB is investing in the early clinical development of proprietary candidates
- ▶ R&D spend will increase modestly to maintain the momentum of proprietary candidate development, at the same time as investing in bioprocessing capacity expansion

Net cash/capital increases



- ▶ On 9 March 2018, the company raised new funds of £19.3m (net) through a Placing of shares at 587.5p for investment in manufacturing capacity
- ▶ At 31 December 2018, OXB had net debt of -£8.9m, compared with -£22.5m on 31 December 2017, composed of £32.2m cash and £41.2m debt
- ▶ In June 2019, OXB raised new funds of £53.5m (gross) through equity financing from Novo Holdings A/S, which is being used to repay the debt

Free cashflow



- ▶ Actual cash fluctuates, dependent on the timing of receipt of milestones and royalties
- ▶ OXB is expected to turn free cashflow positive in FY’20
- ▶ Free cashflow will be affected by the investment being made to increase bioprocessing manufacturing capacity and its timing

Source: Company data; Hardman & Co Life Sciences Research

Novo Holdings strategic investment

Key features

- ▶ **Equity financing:** OXB has secured equity financing of £53.5m from Novo Holdings A/S. It has been invested in two parts: the first, £45.3m in return for 6,568,024 new Ordinary shares at 690p, was issued on 3 June 2019. The second subscription for a further 1,181,976 new Ordinary shares was issued at the same price on 4 June 2019.
- ▶ **Repayment of \$55m loan:** The investment allows OXB to pay off its relatively expensive \$55m loan from Oakland Capital Management. Interest of 9% plus three-month US\$ LIBOR has been paid since the loan was first drawn down in June 2017. With another interest payment due in 2019, repayment of the loan is expected to provide OXB with a completely de-leveraged balance sheet by 30 June 2019, the interim period-end, and greater financing flexibility going forward.
- ▶ **Strategic investment:** In addition to providing capital to earlier stage companies, Novo Holdings A/S also invests in growth equity to market-leading life sciences companies. Given its network, sector expertise and the long-term nature of its financing approach, this investment will act as a partnership, in addition to being further validation of OXB's growth potential from an expert investor.

Capital increase

Share capital

Novo Holdings has invested £53.5m in OXB in return for a total 7,750,000 new ordinary shares, representing 10.1% of the outstanding shares following the capital increase. Immediately prior to the subscription (31 May 2019), OXB had 68,987,856 Ordinary shares of 50p in issue. The new shares represented 11.2% of the existing capital at that point and were issued without a General Meeting as their issue was covered by existing shareholder authorities.


The first 6,568,024 new Ordinary shares (the subscription shares) were issued to Novo Holdings on 3 June 2019, at £6.90, providing OXB with £45,319,365 gross. The remaining 1,181,976 reflected a 'subscription option' at the same price; with the shares responding positively to the initial announcement, this subscription option was exercised on 4 June 2019, raising a further £8,155,634 gross new capital.

Post capital increase					
Subscription agreement	Issue date	# Novo shares	Novo investment	OXB shares outstanding	% Novo holding
At 31 May 2019				68,987,856	
Subscription shares	3 June 2019	6,568,024	£45.3m	75,555,880	8.7%
Subscription option	4 June 2019	1,181,976	£8.16m	76,737,856	1.5%
Total		7,750,000	£53.5m	76,737,856	10.1%

Source: Company announcements, Hardman & Co Life Sciences Research

Share register

Following issue of the subscription shares, Novo Holdings A/S has become OXB's third biggest shareholder. All else being equal at the time of writing (11 June 2019), the chart below shows the changed major shareholdings following the issue.



Source: Company reports, newswires, Hardman & Co Life Sciences Research

Loan repayment

Oaktree Capital Management loan

On 30 June 2017, OXB announced a \$55m loan agreement with Oaktree Capital Management LLP, which was used to fully repay its existing \$50m loan and 'true-up' from Oberland Capital Healthcare. The terms of the new Oaktree loan were more favourable and had less stringent requirements regarding minimum cash balances that needed to be held, at \$5m/£3.8m.

At the end of 1H'17, \$50m of the Oaktree facility had been drawn down, with the fair value of the capital less capitalised legal and other costs appearing as long-term loans on the balance sheet (£33.9m), and the fair value of the associated warrants shown as equity (£1.2m). The remaining \$5m/£3.8m of the loan was drawn down during July 2017.

Repayment

In March 2018, OXB undertook a share Placing to provide the funds required to invest in new manufacturing capacity to satisfy the increasing demand for its LentiVector platform. This, together with an improving operating performance in 2018, left the company in a much stronger financial position. Consequently, the Oaktree loan was looking increasingly expensive, carrying interest of 9% plus three-month US\$ LIBOR, which was being paid in dollars every three months, in arrears. At the 2018 results presentation, management assured the market that all options were being considered for refinancing this loan. Following the Novo investment, OXB has stated that it will repay the loan in full, together with any interest due and a modest exit fee, and we expect this to take place by 29 June 2019, i.e. one year before the loan was due to mature.

Debt was refinanced using \$55m Oaktree Capital loan in 1H'17...

...with less stringent requirements for minimum cash balances than previous loan...

...and final \$5m was drawn down in July 2017

The agreement with Novo Holdings A/S has come at just the right time, avoiding 12 months of interest for 2H'19 and 1H'20 before maturity on 29 June 2020. Subject to achieving certain revenue conditions, the interest rate could have dropped by 0.25% in both the second and third years of the loan; whether these conditions were met has not been disclosed. In the table below, we have assumed that the loan is repaid on 29 June 2019, along with the exit fee (part expensed over the course of the loan). Although the 2017 annual report states: '...the Oaktree loan is repayable no later than 29 June 2020 although it may be repaid, at the group's discretion, at any time subject to early pre-payment fees and an exit fee...', we understand that pre-payment fees were only payable in the first two years of the loan.

Estimated approximate repayment of Oaktree loan

	30 Jun 2017	31 Dec 2017	31 Dec 2018	29 Jun 2019	Estimated cash repayment by 29 Jun 2019
Capital \$m	-50.00	-55.00	-55.00	-55.00	
£m	-38.49	-40.71	-41.92	-43.34	-43.34
Interest accrued \$m	0	-2.92	-6.22	-3.19	
£m	0	-2.16	-4.87	-2.51	
Interest paid in period \$m	0	-1.57	-5.96	-4.61	
£m	0	-1.17	-4.67	-3.73	-3.73
Exit fee \$m	-	-	-	-0.50	
£m	-	-	-	-0.39	-0.39
Total owed £m					-47.36

*£ amounts calculated using period-end spot rate except 29 June 2019, which uses 28 May 2019 spot rate
Source: Hardman & Co Life Sciences Research*

Strengthened company

Clean balance sheet

Following early repayment of the loan using the proceeds from the Novo Holdings investment, OXB will have a clean and ungeared balance sheet. Forecasts show that OXB will have a gross cash position at 31 December 2019 of £34.8m and no debt.

Summary of change in net cash/(debt)

Year-end Dec (£m)	31 Dec 2018 actual	30 Jun 2019 forecast	31 Dec 2019 forecast
Cashflow from operations	-9.97	18.70	16.83
Strategic investment	0.00	52.43	52.43
Loan/interest repayment	-4.61	-47.36	-47.36
Cash	32.24	45.54	34.80
Debt	-41.15	0.00	0.00
Net cash/(debt)	-8.91	45.54	34.80

Source: Hardman & Co Life Sciences Research

Investment summary

Combined with its first profitable period (underlying EBIT of £9.18m) in 2018, OXB is clearly a strengthened company. It no longer has to ringfence \$5m/£3.8m in cash and it is not subject to ongoing interest payments, giving the company far more financial flexibility going forward, particularly important during its period of manufacturing capacity expansion. It is now cashflow positive at the operational level (see full financial tables at the back of report) and is expected to be free cashflow (FCF) positive in 2020, although FCF will be lumpy in the next 18 months due to the variability of capital expenditure.

Note that our forecasts assume that no further deals are announced, so they are conservative, although we do assume further milestone payments from existing partners in 2019.

The table below illustrates the changes to forecasts following the investment by Novo Holdings and the loan repayment. EPS is significantly improved in both 2019 and 2020, at 24.4p in 2020, or 22.4p on a fully diluted basis.

Year-end Dec (£m)	2019E			2020E		
	Old	New	Change	Old	New	Change
Gross income	83.1	n/c	-	104.6	n/c	-
Group sales	54.1	n/c	-	78.7	n/c	-
Other income	29.0	n/c	-	25.9	n/c	-
EBITDA	14.6	n/c	-	18.5	n/c	-
Underlying EBIT	9.84	n/c	-	13.27	n/c	-
Net interest	-4.08	-2.15	-47%	-4.05	0.45	-111%
U/I net income	8.29	9.91	+20%	12.43	16.17	+30%
U/I EPS	12.53	13.68	+9%	18.79	24.35	+30%
U/I fully diluted EPS	11.60	12.69	+9%	17.37	22.42	+29%
Net cash/(debt)	-9.12	34.80	-482%	-1.86	43.82	-2456%
OCFPS	23.08	22.09	-4%	20.59	26.26	+28%
P/E	51.95	53.53	+3%	36.19	30.06	-17%
EV/FCF	6,831.3	-78.96	-101%	64.05	57.88	-10%

U/I = underlying; n/c = no change; OCFPS = operating cash flow per share
Source: Hardman & Co Life Sciences Research


Our sum-of-the-parts valuation has been updated to reflect the net cash position and increased number of shares in issue following the subscription (with no alterations to any assumptions or to the rNPV of OXB's royalty streams or proprietary portfolio). This produced an updated risk-adjusted market capitalisation of £731m (cf £582m prior to the announcement) or 954p/share (cf 880p/share prior to the announcement).

Novo Holdings A/S

The Novo Group is a group of independent companies controlled by the Novo Nordisk Foundation, with Novo Holdings A/S (Novo) serving as the holding company. Novo is a well-known life science investor and is responsible for managing the Foundation's controlling stakes in Novo Nordisk (NOVOOb.CO) and Novozymes (NZYMb.CO), as well as the group's other assets and investments.

In addition to providing capital to earlier-stage companies, the holding company provides growth equity to market-leading companies such as OXB; Novo's portfolio currently consists of 93 companies, contributing a variety of seed, venture and equity financing. Given its provision of evergreen funds, Novo acts as a long-term partner, providing access to its life sciences expertise and network, in addition to capital provision. Novo has an excellent track record, achieving IRR returns of 21% between 2011 and 2016.

This strategic investment should provide support to OXB during its expansion phase, in addition to being very clear validation of the company and its strategy by an expert. How such an investor could affect a potential future takeover of OXB in the future remains an open question. However, there is precedent that suggests that Novo would not be obstructive should such a situation arise: as an 11.4% shareholder in BTG, it has not stood in the way of BTG's acquisition by Boston Scientific Corporation (www.BTGplc.com).



Source: Novo Holdings A/S website

Financials and investment case

Profit & Loss

- ▶ **Gross income:** The sum of bioprocessing sales, commercial development (CD) fees, all licensing income (upfronts and milestones), royalties and grants, shows that our numbers, although presented differently, equate to those reported.
- ▶ **Group sales:** Composed of bioprocessing/CD, this will be the main growth driver over the next three years. 'Other income' is lumpy – forecasts do not include potential new deals, and the timing of future licensing income from existing deals is hard to forecast.
- ▶ **EBITDA:** 2018 was the first profitable year, with EBITDA at £13.5m (-£2.6m) due to an impressive performance in securing partnership deals.
- ▶ **Underlying EBIT:** Despite the significant investment in personnel and R&D, the overall outcome for the underlying EBIT in 2019 is forecast to be in line with fiscal 2018. Increases in R&D are likely to be supported by growth in bioprocessing/commercial development sales, dependent on partners' progress.

Profit & Loss account						
Year-end Dec (£m)	2016	2017	2018	2019E	2020E	2021E
GBP:\$	1.354	1.289	1.312	1.312	1.312	1.312
Gross income (as reported)	30.78	39.36	67.84	83.47	104.60	123.04
Group sales	27.78	31.49	39.63	54.13	78.70	89.80
COGS	-11.84	-18.44	-22.76	-31.40	-44.07	-44.90
Gross profit	15.94	13.05	16.86	22.74	34.63	44.90
Gross margin	49.9%	35.2%	42.6%	42.0%	44.0%	50.0%
SG&A	-5.09	-6.31	-6.19	-8.12	-9.44	-9.88
R&D	-24.30	-21.61	-29.71	-34.10	-37.78	-43.10
EBITDA	-6.78	-2.63	13.54	14.63	18.53	30.40
Depreciation	-3.34	-4.11	-4.33	-4.77	-5.24	-5.24
Amortisation	-0.34	-0.26	-0.03	-0.03	-0.03	0.00
Other income	3.00	7.87	28.21	29.33	25.86	33.24
Underlying EBIT	-10.45	-7.00	9.18	9.84	13.27	25.16
EBIT margin	37.6%	-22.2%	23.2%	18.2%	16.9%	28.0%
Share-based costs	-0.87	-0.97	-1.25	-1.35	-1.45	-1.55
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
Statutory EBIT	-11.32	-7.97	7.93	8.50	11.82	23.62
Net interest	-4.89	-9.38	-4.61	-2.18	0.39	0.54
Forex gain/loss	-4.11	5.58	-4.29	0.00	0.00	0.00
Revaluation of investments	0.00	2.30	5.98	0.00	0.00	0.00
Underlying pre-tax profit	-15.34	-16.38	4.57	7.67	13.66	25.71
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
Statutory pre-tax profit	-20.31	-11.76	5.01	5.93	12.21	24.16
Tax payable/credit	3.67	2.74	2.53	2.22	2.46	2.80
Underlying net income	-11.67	-13.61	7.09	9.88	16.11	28.51
Statutory net income	-16.64	-9.02	7.54	8.14	14.67	26.96
Ordinary 50p shares:						
Period-end (m)	61.76	62.15	66.17	76.61	76.61	61.77
Weighted average (m)	55.56	61.91	65.19	72.26	66.17	66.17
Fully diluted (m)	58.00	67.03	70.70	77.88	71.89	71.99
Underlying basic EPS (p)	-21.00	-21.99	10.88	13.68	24.35	43.08
Statutory basic EPS (p)	-29.95	-14.56	11.57	11.27	22.17	40.75
U/I fully diluted EPS (p)	-20.12	-20.31	10.03	12.69	22.42	39.60
Stat. fully diluted EPS (p)	-28.70	-13.45	10.67	10.45	20.40	37.45
DPS (p)	0.00	0.00	0.00	0.00	0.00	0.00

Source: Hardman & Co Life Sciences Research

Balance sheet

- ▶ **Trade debtors:** There was a noticeable ca.£10m increase in trade debtors at the year-end to £15.4m (£5.7m), suggesting that several invoices were issued late in the year. This has an impact on the working capital requirement for the group.
- ▶ **Cash:** 'Other income' in the P&L mostly drops straight through the cashflow statement, benefiting the period-end cash balance. Following the 2018 Placing and the 1H'19 strategic investment, the cash position is expected to remain strong throughout the forecast period, supporting the planned investment in manufacturing facilities and internal R&D programmes.
- ▶ **Loan facility:** The increase in the long-term debt in 2018 was mostly due to the accrued interest on the loan. The weakness of sterling over the reporting period resulted in a forex conversion loss of £4.3m. We expect the loan to be repaid in 1H'19, strengthening the balance sheet and removing forex risk.
- ▶ **Net cash:** At 31 December 2018, the net debt was -£8.9m, but the company is likely to remain net cash positive going forward, despite the capex programme to increase manufacturing capacity and bioprocessing efficiency.

Balance sheet						
@31 Dec (£m)	2016	2017	2018	2019E	2020E	2021E
Shareholders' funds	12.62	6.70	34.74	95.31	110.08	137.14
Cumulated goodwill	0.00	0.00	0.00	0.00	0.00	0.00
Total equity	12.62	6.70	34.74	95.31	110.08	137.14
Share capital	30.88	31.08	33.03	38.31	38.31	38.31
Reserves	-18.26	-24.38	1.71	57.01	71.77	98.84
Provisions/liabilities	3.94	14.20	24.81	12.40	0.62	0.00
Deferred tax	0.00	0.00	0.28	0.28	0.28	0.28
Long-term loans	34.39	36.86	41.15	0.00	0.00	0.00
Short-term debt	0.00	0.00	0.00	0.00	0.00	0.00
less: Cash	15.34	14.33	32.24	34.80	43.82	64.93
less: Non-core investments	0.66	2.95	10.97	10.97	10.97	10.97
Invested capital	34.95	40.48	57.77	62.23	56.20	61.53
Fixed assets	27.51	25.37	31.79	49.53	52.74	55.14
Intangible assets	1.33	0.10	0.12	0.12	0.12	0.12
Inventories	2.20	3.33	4.25	5.81	8.44	9.63
Trade debtors	1.97	5.71	15.41	12.33	14.79	17.75
Other debtors	4.94	11.93	15.18	15.18	15.18	15.18
Tax liability/credit	3.00	2.78	2.45	2.53	2.22	2.46
Trade creditors	-1.58	-3.68	-3.75	-5.17	-7.25	-7.39
Other creditors	-4.43	-5.05	-7.68	-18.08	-30.04	-31.35
Debtors less creditors	3.90	11.68	21.61	6.78	-5.11	-3.36
Invested capital	34.95	40.48	57.77	62.23	56.20	61.53
Net cash/(debt)	-19.05	-22.54	-8.91	34.80	43.82	64.93

Source: Hardman & Co Life Sciences Research

Cashflow

- ▶ **Working capital:** In prior years, since much of OXB's work is on a fee-for-service basis, there was no major working capital requirement for the group. However, an increase in the number of partners, preparation for clinical trials and commercialisation of partners' products, has required a short-term increase in working capital requirements. There was a noticeable increase in trade debtors at the FY'18 period-end, which has an impact on receivables, increasing to £14.6m in 2018, much of which is expected to be received in FY'19.
- ▶ **Free cashflow:** Counterbalancing the temporary increase in working capital, operating cashflow increased £10.0m, delivering operating cash flow per share (OCFPS) of 13.8p at the 2018 full year. A large, but planned, increase in capex as part of the capacity expansion in 2019 means that OXB is now forecast to turn FCF positive in 2020.

Cashflow						
Year-end Dec (£m)	2016	2017	2018	2019E	2020E	2021E
Underlying EBIT	-10.45	-7.00	9.18	9.84	13.27	25.16
Depreciation	3.34	4.11	4.33	4.77	5.24	5.24
Amortisation	0.34	0.26	0.03	0.03	0.03	0.00
<i>Inventories</i>	0.50	-1.13	-0.92	-1.56	-2.64	-1.19
<i>Receivables</i>	4.03	-10.73	-14.56	3.08	-2.47	-2.96
<i>Payables</i>	-3.28	2.73	2.73	1.42	2.09	0.14
Change in working capital	1.25	-9.13	-12.75	2.95	-3.02	-4.01
Exceptionals/provisions	-0.75	10.27	10.45	-0.75	-0.75	-0.75
Disposals	0.00	0.00	0.00	0.00	0.00	0.00
Other	0.35	1.27	-1.27	0.00	0.00	0.00
Company op. cashflow	-5.93	-0.22	9.97	16.83	14.77	25.64
Net interest	-3.21	-10.76	-4.61	-3.40	0.39	0.54
Tax paid/received	4.08	3.51	3.65	2.53	2.22	2.46
Operational cashflow	-5.06	-7.47	9.01	15.96	17.38	28.64
Capital expenditure	-6.46	-1.97	-10.10	-22.50	-8.46	-7.63
Sale of fixed assets	0.00	0.00	0.00	0.00	0.00	0.00
Free cashflow	-11.52	-9.44	-1.09	-6.54	8.92	21.01
Dividends	0.00	0.00	0.00	0.00	0.00	0.00
Acquisitions	0.00	0.00	-0.05	0.00	0.00	0.00
Disposals	0.00	0.00	0.00	0.00	0.00	0.00
Other investments	0.00	0.00	-0.76	0.00	0.00	0.00
Cashflow after investments	-11.52	-9.44	-1.89	-6.54	8.92	21.01
Share repurchases	0.00	0.00	0.00	0.00	0.00	0.00
Share issues	17.50	0.39	19.81	52.43	0.10	0.10
Currency effect	-7.13	-2.79	-4.29	0.00	0.00	0.00
Loans/cash acquired	0.00	8.36	0.00	-43.34	0.00	0.00
Change in net cash/(debt)	-1.15	-3.48	13.63	2.56	9.02	21.11
OCFPS (p)	-9.11	-12.06	13.83	22.09	26.26	43.28
Opening net cash	-17.90	-19.05	-22.54	-8.91	34.80	43.82
Closing net cash/(debt)	-19.05	-22.53	-8.91	34.80	43.82	64.93

Source: Hardman & Co Life Sciences Research

Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legals/research-disclosures>. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)



research@hardmanandco.com

35 New Broad Street
London
EC2M 1NH

+44(0)20 7194 7622

www.hardmanandco.com